The Lobbying Register, read carefully Epicycle

Returns

Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.

Clear all

Showing returns filed by Hanover Media Strategy Limited .

Filed returns
110
match these filters
Matching filed returns per period 0 2 5 7 10 Jan–Apr 2017: 1 filed returns May–Aug 2017: 5 filed returns Sep–Dec 2017: 5 filed returns Jan–Apr 2018: 2 filed returns May–Aug 2018: 1 filed returns Sep–Dec 2018: 1 filed returns Jan–Apr 2019: 3 filed returns May–Aug 2019: 2 filed returns Sep–Dec 2019: 3 filed returns Jan–Apr 2020: 4 filed returns May–Aug 2020: 5 filed returns Sep–Dec 2020: 6 filed returns Jan–Apr 2021: 3 filed returns May–Aug 2021: 4 filed returns Sep–Dec 2021: 3 filed returns Jan–Apr 2022: 2 filed returns May–Aug 2022: 3 filed returns Sep–Dec 2022: 3 filed returns Jan–Apr 2023: 6 filed returns May–Aug 2023: 6 filed returns Sep–Dec 2023: 9 filed returns Jan–Apr 2024: 6 filed returns May–Aug 2024: 5 filed returns Sep–Dec 2024: 7 filed returns Jan–Apr 2025: 3 filed returns May–Aug 2025: 4 filed returns Sep–Dec 2025: 5 filed returns Jan–Apr 2026: 2 filed returns May–Aug 2026: 1 filed returns 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Filed returns per four-month period Click a column to list its returns.
PeriodRegistrantPolicy areaSubject, as filedOfficials namedLink
Jan–Apr 2023 Hanover Media Strategy Limited Health The landscape for innovative and precision medicines in Ireland. (Public policy or programme) 12 On lobbying.ie
Jan–Apr 2023 Hanover Media Strategy Limited Health Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) 12 On lobbying.ie
Jan–Apr 2023 Hanover Media Strategy Limited Health EU regulation on substances of human origin (Legislation) 2 On lobbying.ie
Jan–Apr 2023 Hanover Media Strategy Limited Health Rare Disease Policy (Legislation) 17 On lobbying.ie
Sep–Dec 2022 Hanover Media Strategy Limited Health Briefing on AstraZeneca's operations in Ireland. (Public policy or programme) 2 On lobbying.ie
Sep–Dec 2022 Hanover Media Strategy Limited Health Request for a meeting to discuss the landscape for innovative and precision medicines in Ireland. (Public policy or programme) 18 On lobbying.ie
Sep–Dec 2022 Hanover Media Strategy Limited Health Rare Disease Policy (Legislation) 9 On lobbying.ie
May–Aug 2022 Hanover Media Strategy Limited Health Briefing on AstraZeneca's operations in Ireland. (Public policy or programme) 2 On lobbying.ie
May–Aug 2022 Hanover Media Strategy Limited Health Visit to the Alexion, AstraZeneca Rare Disease facility in Athlone. (Public policy or programme) 2 On lobbying.ie
May–Aug 2022 Hanover Media Strategy Limited Health Meeting to discuss the reimbursement landscape and access challenges for personalised medicines in Ireland. (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2022 Hanover Media Strategy Limited Health Introducing Horizon and its presence in Ireland (Public policy or programme) 16 On lobbying.ie
Jan–Apr 2022 Hanover Media Strategy Limited Health Update on AstraZeneca sponsored roundtable outcomes held for Chronic Obstructive Pulmonary Disease (Public policy or programme) 14 On lobbying.ie
Sep–Dec 2021 Hanover Media Strategy Limited Health Partnership for Health System Sustainability and Resilience (Public policy or programme) 4 On lobbying.ie
Sep–Dec 2021 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 4 On lobbying.ie
Sep–Dec 2021 Hanover Media Strategy Limited Health Update on AstraZeneca COVID-19 vaccine and therapies (Public policy or programme) 5 On lobbying.ie
May–Aug 2021 Hanover Media Strategy Limited Health Update on COVID-19 Vaccine AstraZeneca (Public policy or programme) 8 On lobbying.ie
May–Aug 2021 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 9 On lobbying.ie
May–Aug 2021 Hanover Media Strategy Limited Health Medicines Access for Irish patients with rare diseases (Legislation) 1 On lobbying.ie
May–Aug 2021 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 9 On lobbying.ie
Jan–Apr 2021 Hanover Media Strategy Limited Health Update on COVID-19 Vaccine AstraZeneca (Public policy or programme) 15 On lobbying.ie
Jan–Apr 2021 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 15 On lobbying.ie
Jan–Apr 2021 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 9 On lobbying.ie
Sep–Dec 2020 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Public policy or programme) 5 On lobbying.ie
Sep–Dec 2020 Hanover Media Strategy Limited Health Engagement on National Screening Advisory Committee Bill 2020 and the newborn screening programme (Legislation) 1 On lobbying.ie
Sep–Dec 2020 Hanover Media Strategy Limited Health Centralised Services for Rare Disease Medicines (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2020 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 14 On lobbying.ie
Sep–Dec 2020 Hanover Media Strategy Limited Health Provided update to select politicians on developments in Oncology therapies and barriers to access (Matters involving public funds) 4 On lobbying.ie
Sep–Dec 2020 Hanover Media Strategy Limited Health Briefed select parliamentarians on potential Covid-19 vaccine (Public policy or programme) 22 On lobbying.ie
May–Aug 2020 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 10 On lobbying.ie
May–Aug 2020 Hanover Media Strategy Limited Health Update on potential COVID-19 Vaccine (Matters involving public funds) 4 On lobbying.ie
May–Aug 2020 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) 10 On lobbying.ie
May–Aug 2020 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 16 On lobbying.ie
May–Aug 2020 Hanover Media Strategy Limited Health Optimisation of Rheumatoid Arthritis pathway of care (Matters involving public funds) 2 On lobbying.ie
Jan–Apr 2020 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 5 On lobbying.ie
Jan–Apr 2020 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 4 On lobbying.ie
Jan–Apr 2020 Hanover Media Strategy Limited Health Optimisation of Rheumatoid Arthritis pathway of care (Matters involving public funds) 10 On lobbying.ie
Jan–Apr 2020 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) 8 On lobbying.ie
Sep–Dec 2019 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) 2 On lobbying.ie
Sep–Dec 2019 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 1 On lobbying.ie
Sep–Dec 2019 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) 7 On lobbying.ie
May–Aug 2019 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 4 On lobbying.ie
May–Aug 2019 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) 15 On lobbying.ie
Jan–Apr 2019 Hanover Media Strategy Limited Health Engaged Government Ministers on patient safety, STEM education and healthcare innovation (Public policy or programme) 4 On lobbying.ie
Jan–Apr 2019 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 5 On lobbying.ie
Jan–Apr 2019 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) 10 On lobbying.ie
Sep–Dec 2018 Hanover Media Strategy Limited Health Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) 10 On lobbying.ie
May–Aug 2018 Hanover Media Strategy Limited Health Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) 13 On lobbying.ie
Jan–Apr 2018 Hanover Media Strategy Limited Health Reimbursement of Vimizim for Morquio A Syndrome (Matters involving public funds) 12 On lobbying.ie
Jan–Apr 2018 Hanover Media Strategy Limited Health Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) 12 On lobbying.ie
Sep–Dec 2017 Hanover Media Strategy Limited Health Reimbursement of Vimizim for Morquio A Syndome (Matters involving public funds) 16 On lobbying.ie

Policy areas in these returns

Public policy areaFiled returnsShareRelative to the largest
Health 110 100.0%